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ABSTRACT Lung surfactant adsorption to an air-water interface is strongly inhibited by an energy barrier imposed by the
competitive adsorption of albumin and other surface-active serum proteins that are present in the lung during acute respiratory
distress syndrome. This reduction in surfactant adsorption results in an increased surface tension in the lung and an increase in the
work of breathing. The reduction in surfactant adsorption is quantitatively described using a variation of the classical Smolukowski
analysis of colloid stability. Albumin adsorbed to the interface induces an energy barrier to surfactant diffusion of order 5 kBT,
leading to a reduction in adsorption equivalent to reducing the surfactant concentration by a factor of 100. Adding hydrophilic,
nonadsorbing polymers such as polyethylene glycol to the subphase provides a depletion attraction between the surfactant
aggregates and the interface that eliminates the energy barrier. Surfactant adsorption increases exponentially with polymer
concentration as predicted by the simple Asakura andOosawamodel of depletion attraction. Depletion forces can likely be used to
overcome barriers to adsorption at a variety of liquid-vapor and solid-liquid interfaces.
INTRODUCTION
The surface tension control imposed by lung surfactant (LS),
a unique mixture of lipids and proteins that lowers the in-
terfacial tension in the lungs and facilitates normal breathing
(1–3), is compromised during acute respiratory distress
syndrome (ARDS) (4). Lung surfactant is a mixture of lipids
(primarily dipalmitoylphosphatidylcholine) and four lung
surfactant-speciﬁc proteins (SP-A, B, C, and D) that lines the
interior of the lung alveoli and acts to lower the interfacial
tension in the lungs, thereby insuring a negligible work of
breathing and uniform lung inﬂation (1). The absence of lung
surfactant due to prematurity leads to neonatal Respiratory
Distress Syndrome (NRDS) (1,2,5,6). Treating NRDS with
currently available replacement surfactants has signiﬁcantly
reduced neonatal mortality in developed countries (1,2,5,6).
However, replacement surfactant treatment has been disap-
pointing when used to treat lung diseases associated with
lung injury and acute respiratory distress syndrome (7–9). In
such cases, surfactant somehow loses the ability to reduce
surface tension and is said to be ‘‘inactivated’’ (2,10–12). A
common factor among ARDS patients is elevated levels of
serum and inﬂammatory proteins in the bronchial and
alveolar ﬂuid (2,4,13–15) and reduced LS function (13). In
vitro, LS mixed with serum proteins shows an ARDS-like
depression of surfactant activity (2,16–18) and surfactant
inactivation caused by serum leakage into alveoli is one
reason why treatment of lung injuries with replacement sur-
factant are believed to be unsuccessful (16,19). Several non-
ionic and anionic polymers have recently been shown to
enhance the ability of clinical surfactants to resist inactiva-
tion by serum and other substances both in vitro and in vivo
(10,18,20–29). Lung function of animals with lung injury is
markedly improved when polymers are added to clinical
surfactants used for treatment of NRDS (10,12,24,30–32).
Here we show that one cause of surfactant inactivation is
the formation of an interfacial ﬁlm of albumin that reduces or
even eliminates the normal adsorption of LS from solution to
the interface in vitro, resulting in higher than normal surface
tension (2,16–18,26,33). Albumin (and many other serum
proteins found in the bronchial ﬂuid of ARDS patients) is
surface-active and has a surface pressure, P (P ¼ gw-g, gw
is the surface tension of a clean water interface, 72 mN/m,
and g the measured surface tension) that is a logarithmic
function of protein concentration up to a saturation concen-
tration, which is ;1 mg/ml for albumin (17,34,35). The sur-
face pressure at the saturation concentration for albumin and
other serum proteins is between 18 and 25 mN/m (surface
tension of 47–54 mN/m).
This competitive adsorption of albumin to the alveolar air-
liquid interface leads to an energy barrier to surfactant ad-
sorption (18,26). If insufﬁcient functional surfactant reaches
the alveolar interface, the low surface tensions required for
proper lung function are not reached and the work of breath-
ing increases, along with the potential for further inﬂamma-
tion and injury, consistent with the development of ARDS.
However, our experiments also show that a polymer-induced
‘‘depletion attraction’’ can overcome the repulsive energy bar-
rier, thereby restoring normal surfactant adsorption, even in
the presence of high albumin concentrations (16,18). The
depletion attraction effectively pushes surfactant aggregates
toward the interface due to the increased polymer entropy
induced by the elimination of the ‘‘excluded volumes’’ of
the surfactant aggregates and the interface (26,36) as the
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surfactant ﬂocculates or is adsorbed to the interface. The
depletion attraction is sufﬁciently strong that it can overcome
the electrostatic and steric repulsion imposed by serum or
albumin already adsorbed to the interface (26). One require-
ment for the depletion attraction to operate is that the poly-
mer not adsorb signiﬁcantly to the surfactant aggregates or to
the air-water interface. Polyethylene glycol (PEG) is not
particularly surface-active; a 1 wt % solution reduces the
surface tension from 72 mN/m to ;64 mN/m.
METHODS
Survanta (Abbott Laboratories, Columbus, OH) was obtained from the San
Francisco General Hospital nursery. Survanta is an organic extract of minced
bovine lungs that contains 80–90 wt % phosphatidylcholine, of which ;70
wt % is saturated dipalmitoylphosphatidylcholine. There is ,2 wt % of the
lung surfactant speciﬁc proteins SP-B (,0.5 wt %) and SP-C (1.5 wt %).
There are ;5 wt % negatively charged phospholipids including phosphat-
idylglycerol and phosphatidylserine, and ;10 wt % palmitic acid (37).
Survanta and other clinical lung surfactants form multi-micron bilayer
aggregates in buffered saline solution. Polyethylene glycol (PEG; 10 kDa),
and bovine serum albumin were obtained from Sigma (St. Louis, MO).
Isotherms were recorded at 25C (no signiﬁcant changes are seen from 23–
37C (38)) using a custom stainless steel ribbon trough (Nima, Coventry,
England) equipped with a Wilhelmy plate (39,40). The trough had a surface
area of 130 cm2, a subphase volume of 150 mL, and a typical compression/
expansion cycle took 8 min. Survanta was diluted in buffer (NaCl 150 mM,
CaCl2 2 mM, and NaHCO3 0.2 mM, pH ¼ 7) to a lipid concentration of
2 mg/ml and was deposited dropwise into the subphase of the Langmuir
trough at the stated total surfactant concentrations to initiate each adsorption
experiment. Albumin and PEG were dissolved in the same buffer at the
stated concentrations for subsequent experiments.
A Nikon Optiphot optical microscope (Nikon, Tokyo, Japan) was posi-
tioned above the trough with a 503 extra-long working distance objective
(Nikon) designed for ﬂuorescent light. Full-length movies and individual
frames were recorded directly to computer (Moviestar, Mountain View,
CA). Contrast in the images was due to segregation of 1 mol % ﬂuorescent
lipid Texas Red-DHPE (Molecular Probes, Eugene, OR) between the ﬂuid
phase, which appears bright in images, and the condensed phase, which
appears dark in the ﬁlms containing Survanta. The albumin was not labeled
and does not ﬂuoresce.
RESULTS
Fig. 1 a is a typical expansion-compression cyclic isotherm for
800 mg of the clinical lung surfactant, Survanta, adsorbing to
FIGURE 1 Cyclic isotherms of Survanta
on various subphases. (a) 800 mg Survanta on
a clean buffered saline subphase. On com-
pression, the surface pressure increases until
the isotherm has a characteristic shoulder at
40 mN/m. This corresponds to rearrange-
ment of the unsaturated lipids and surfactant
proteins SP-B and SP-C in the ﬁlm (38). On
further compression, the surface pressure
rises abruptly to the collapse pressure of 65
mN/m. At this surface pressure, the ﬁlm
begins to ‘‘collapse’’ and forms cracks and
folds as seen in Fig. 2 b. Film collapse
determines the minimum surface tension
possible for a given surfactant. On expansion,
the surface pressure drops to 10 mN/m; lung
surfactant isotherms exhibit signiﬁcant hys-
teresis between the compression and expan-
sion parts of the cycle. The cracks and folds
in the monolayer begin to unfold and heal at
these low surface pressures on expansion,
which accounts for much of the hysteresis
(17). (b) 800 mg Survanta on saline buffer
containing 2 mg/mL albumin. The character-
istic shoulder and collapse plateau on com-
pression seen in panel a cannot be reached
with albumin in the subphase, and the surface
pressure does not rise to 40 mN/m. Albumin
concentrations in ARDS alveolar ﬂuid may
reach 100 mg/ml, with an average concentration of 25 mg/ml (35); the concentrations used here are signiﬁcantly lower than typically found in ARDS patients.
The albumin prevents surfactant from reaching the interface and spreading as shown in Fig. 2, c and d. (c) Increasing the Survanta concentration to 3800 mg on
saline buffer containing 2 mg/mL albumin does not restore the isotherm in panel a, and although the surface pressure does rise sufﬁciently that the shoulder at
40 mN/m is visible, the collapse plateau is not reached. Less surfactant adsorbs to the interface that for a clean interface, even though the total surfactant
concentration has increased. (d) 800 mg Survanta on saline buffer containing 2 mg/mL albumin and 1.2 wt % polyethylene glycol (PEG) polymer of 10 K
molecular weight. The characteristic shoulder and collapse plateau of panel a have been restored with little change in surface pressure showing that the PEG
reverses the albumin inhibition. The only difference with the isotherm in panel a is that the minimum surface pressure is;20 mN/m with PEG in the subphase
(18). This suggests that the PEG also helps the collapsed monolayer to heal at higher surface pressures, along with increasing surfactant adsorption to the
interface.
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a clean, buffered-saline interface. The isotherm traces over
itself on subsequent cycles, and on compression exhibits a
characteristic shoulder at P ;40 mN/m, and a collapse
plateau at Pmax ;65 mN/m (38), indicative of good
surfactant performance (2). The hysteresis between com-
pression and expansion cycles is typical of Survanta and
other clinical and natural lung surfactant isotherms (2,17,41).
Reexpanding the interface after monolayer collapse leads to
a rapid drop in surface pressure to ;10 mN/m, which is
maintained until compression is resumed (2,38). In general,
collapse structures do not readsorb to the interface until the
surface pressure is rather low, resulting in the expansion and
compression hysteresis (17). There is no signiﬁcant change
in the Survanta isotherm from 23 to 37C (38), so most
experiments were done at room temperature.
Fluorescence images of Survanta ﬁlms (dopedwith 1mol%
Texas Red-DHPE; Molecular Probes) at the air-subphase
interface show the mottled bright and dark textures typical
of a phase-separated lipid/protein monolayer (Fig. 2 a; P ¼
18 mN/m) and the cracks and folds (arrows) typical at
monolayer collapse, which determines the maximum surface
pressure,Pmax that can be achieved by a given ﬁlm (Fig. 2 b;
Pmax ¼ 66 mN/m, surface tension of;6 mN/m) (38,42,43).
In contrast, when 800 mg Survanta is deposited on a
buffered subphase containing 2 mg/ml albumin (Fig. 1 b),
the surface pressure does not increase above 40 mN/m even
at the smallest trough area; the compression isotherm is not
signiﬁcantly different than that for albumin alone (see Fig.
3 b). The ﬂuorescence images are featureless (Fig. 2 c) or
show isolated, out-of-focus bright spots (Fig. 2 d) indicative
FIGURE 2 Fluorescence images of 800 mg Survanta
spread at varying subphase compositions. Images are
180 mm by 250 mm. The left column is for each
subphase composition at P ¼ 18 mN/m (a, c, e, g) and
the right column is for each subphase at the maximum
surface pressure reached during the cycle (66, 40, 31,
and 38 mN/m, respectively for b, d, f, and h). (Row 1)
Survanta on a clean, buffered subphase. (a) Mottled
texture typical of a phase-separated lipid/protein
monolayer. The mottled texture is found at all surface
pressures from 0 to collapse. (b) Arrows denote cracks
where material is forced from the interface at the
collapse plateau at 66 mN/m. (Row 2) Survanta on
buffer containing 2 mg/mL albumin. (c) At low surface
pressure, no ﬂuorescence is visible showing that the
albumin prevents Survanta from adsorbing to the
interface. (d) After several expansion and compression
cycles (see Fig. 1 b), Survanta comes close to the
interface, but does not spread due to the albumin ﬁlm at
the interface (compare to e–h). (Row 3) (e) During the
ﬁrst cycle for Survanta spread on buffer containing 2
mg/mL albumin and 0.12 wt % PEG, small areas of the
interface are starting to become covered with Survanta.
(f) The Survanta monolayer begins to displace the
albumin (arrow). (Row 4) (g) By the third expansion-
compression cycle for Survanta spread on buffer
containing 2 mg/mL albumin and 0.12 wt % PEG,
larger areas have a morphology similar to Survanta on a
clean interface (Row 1, a and b) in coexistence with
areas similar to albumin (Row 2, c and d). The dotted
white lines denote the borders between the two regions.
0.12 wt % PEG is not sufﬁcient to allow for sufﬁcient
Survanta adsorption to completely displace the albu-
min (See Fig. 3). For ;1 wt % PEG, the images are
identical to Row 1 for all cycles (not shown).
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of Survanta aggregates in the subphase kept from reaching
the interface by the adsorbed albumin ﬁlm. Comparing Fig.
1 c to Fig. 3 a shows that less surfactant adsorbs to the
interface from 3.8 mg of Survanta on an albumin subphase
than from 30 mg of Survanta deposited on a clean subphase.
From the isotherm and the ﬂuorescence images, this ﬁlm still
contains a signiﬁcant albumin fraction.
However, adding 1.2 wt % 10 K molecular weight PEG
(Fig. 1 d) to the albumin subphase restores the isotherm
to that of the clean interface, showing that the polymer
enhances surfactant adsorption (Fig. 1 a). The isotherm in
Fig. 1 d is otherwise identical to that of the clean interface,
conﬁrming that the polymer does not alter the surfactant
monolayer, only the adsorption. Fluorescence images show
that as little as 0.12% PEG in the subphase (Fig. 2, e and f)
causes Survanta to locally break through to the interface,
perhaps at defects in the albumin monolayer (44). Survanta,
which has a higher equilibrium spreading pressure than
albumin (;40 mN/m vs. 22 mN/m (18)) partially replaces
the albumin on the interface. Increasing the polymer concen-
tration to ;1 wt % leads to interface images indistinguish-
able from Fig. 2 a (not shown).
These results can be explained and quantiﬁed using a
variation of the classical Smolukowski analysis of colloid
stability (26). Charged, surface-active serum proteins ad-
sorbed at an interface induce an electrostatic and steric
barrier to surfactant adsorption, similar in magnitude to the
energy barriers responsible for colloidal stability against
ﬂocculation (45). Inactivation reversal by hydrophilic poly-
mers results from adding the ‘‘depletion attraction’’ to the
otherwise repulsive potential induced by the proteins at the
interface. The depletion attraction lowers the energy barrier
to the point that the surfactant aggregates are pushed toward
the interface with sufﬁcient force that the surfactant can
displace the serum proteins.
The driving force for the change in surfactant interfacial
concentration with time, dGdt , is the gradient of a generalized
chemical potential, which results in a diffusive ﬂux multi-







exp ðVmaxÞ=kBT½ ; (1)
where Co is the bulk surfactant concentration, Deff is the
effective surfactant diffusivity, Vmax is the maximum height
of the potential energy barrier (located a distance l from
the interface), kB is Boltzmann’s constant, and T is the
temperature. For small Vmax, surfactant adsorption becomes
diffusion-limited and the interface saturates so adsorption no
longer increases with bulk surfactant concentration. The
height of the potential energy barrier results from several
competing effects,
Vmax ﬃ ðE1  E0Þ1PDA1Eelect1W; (2)
where (E1 – E0) is the energy difference between surfactant
molecules at the interface and in the bulk, which drives
surfactant adsorption. This is opposed by the double-layer
electrostatic potential, Eelect, which depends on the ionic
strength of the subphase and the net charge distribution of the
serum proteins at the interface (46). PDA is a steric term,
FIGURE 3 Fourth compression cycle isotherms of increasing concentrations of Survanta on a clean buffer subphase (a) and 800 mg Survanta on subphases
containing 2 mg/ml albumin with increasing PEG concentrations (b). (a) Up-triangle, 8 mg Survanta; pentagram, 30 mg Survanta; diamond, 80 mg Survanta;
circle, 300 mg Survanta; and square, 800 mg Survanta. At a given surface pressure, the isotherms are translated essentially unchanged from low trough area to
high trough area with increasing Survanta concentration (note the characteristic shoulder at;40 mN/m and the collapse plateau at;65 mN/m). This shows that
Survanta adsorption increases with increasing concentration as suggested by Eq. 1. The interface becomes saturated for concentrations.;300 mg; the 800 mg
isotherm is not displaced signiﬁcantly to higher trough areas. (b) square, Survanta on saline buffer subphase with no albumin; circle, Survanta-albumin;
diamond, Survanta-albumin 0.25 wt % PEG; pentagram, Survanta-albumin 0.50 wt % PEG; and up-triangle, Survanta-albumin 1.2 wt % PEG. The red curve
shows the surface pressure for the albumin subphase with no Survanta or PEG. Comparing to panel a shows that albumin in the subphase produces the same
effect as decreasing the Survanta concentration from 800 mg to;8 mg. Adding increasing amounts of PEG to the subphase shifts the isotherms to higher trough
areas, the same effect as increasing the Survanta concentration in panel a. The shaded area denotes the trough area over which the surface pressure was
averaged for each PEG concentration to obtain the relative surfactant adsorption plotted in Fig. 4.
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which accounts for the energy necessary to clear an inter-
facial area of protein at a surface pressure of P for new
adsorption. The repulsive terms are opposed by the depletion
attraction, as derived from the original Asakura and Oosawa
model for a hard sphere of radius R next to a rigid interface:





attraction is caused by moving a large sphere of radius R to
within l of the interface, thereby freeing its excluded volume
so as to increase the entropy of the polymer (47); fp is the
volume fraction and Rg is the radius of gyration of the
polymer. Albumin and the other serum proteins are of order
4–10 nm in diameter, while the surfactant particles are of the
order of microns; hence, the depletion attraction is signif-
icantly greater for the surfactant particles. The depletion
attraction is purely entropic, and is independent of the chem-
ical composition of the surfactant, protein, and polymer as
long as the polymer does not adsorb to the surfactant or the
interface, which explains why PEG (10,20,24,48), dextran
(21,30), and hyaluronan (18) are all effective at enhancing
surfactant adsorption. Equations 1 and 2 predict an expo-
nential dependence of surfactant adsorption on polymer
concentration, but only a linear dependence on surfactant
concentration in the presence of albumin.
Fig. 3 a shows the surface pressure as a function of trough
area for increasing amounts of Survanta deposited on a clean
saline subphase (38). The characteristic shape of the iso-
therms in Fig. 3 a are translated unchanged (note the shape of
the collapse plateau and the shoulder at ;40 mN/m) from
low to high trough area for a given surface pressure as the
amount of Survanta added to the trough is increased from
8 mg up to 800 mg. This means that the total amount of
surfactant at the interface has increased, as the relationship
between surface pressure and area/molecule is ﬁxed for a
given surfactant composition and temperature (38). Hence,
increasing surfactant adsorption is reﬂected in the isotherms
as a translation from low to high trough area at a given
surface pressure. Eventually, the adsorption saturates (note
the small offset between 300 mg and 800 mg); at this point
surfactant adsorption is diffusion-limited and further in-
creases in surfactant concentration have little effect.
Fig. 3 b shows the effect of albumin on the isotherms is
equivalent to decreasing the Survanta concentration (see
Fig. 3 a). The red line in Fig. 3 b shows the compression
isotherm of 2 mg/ml albumin with no Survanta or PEG,
which differs little from that of 800 mg Survanta on the
albumin subphase. This isotherm is most similar to that of
the 8-mg Survanta isotherm in Fig. 3 a, which means that the
effective surfactant adsorption is reduced by a factor of 100
or more by the albumin. A 100-fold reduction in adsorption
at ﬁxed bulk concentration, Co, corresponds to a Vmax of
;15 kBT in Eq. 1.
Increasing the PEG concentration in the subphase (Fig.
3 b) produces the same effect as increasing the total surfac-
tant concentration on a clean interface (Fig. 3 a), indicating
that the polymer increases surfactant adsorption. However,
as in Fig. 3 a, the shapes of the isotherms are unchanged, just
shifted to larger trough areas with increasing polymer con-
centration, conﬁrming that the albumin and polymer do not
affect the surfactant monolayer properties at the interface,
just the total surfactant adsorption. This is consistent with the
polymer inducing a depletion attraction between the inter-
face and the surfactant aggregates.
Surfactant adsorption is restored to that of a clean inter-
face for ;1 wt % PEG. This suggests that the magnitude of
the depletion interaction is ;5 kBT to offset the repulsive
potential. PEG of molecular weight 10 K has Rg ; 4–5 nm,
and 1 wt % has a volume fraction, fp ; 0.2. R/Rg ; 100
(corresponding to 1 mm diameter surfactant aggregates),
hence the Asakura and Oosawa model gives W ¼ 60 kBT
1 l=2Rg
  2
. This gives the correct magnitude for the
depletion force for l ;1.4 Rg, suggesting that the maximum
in the potential lies;6 nm from the interface. This is roughly
the dimension of the albumin molecules. It is not well
established how the depletion force changes for nonspher-
ical, rough, and deformable surfaces, as is the case for the
surfactant aggregates. However, it is clear that the depletion
interaction lowers the energy barrier to adsorption and dif-
fusion-limited surfactant adsorption is restored.
To quantify the effect of polymer concentration on sur-
factant adsorption, Fig. 4 shows the relative rate of surfactant
adsorption as a function of PEG concentration. The ﬂuores-
cence images (Fig. 2 c) show that in the absence of polymer,
no surfactant adsorbs to the interface. Hence, we deﬁne the
relative adsorption (RA) as the difference between the sample
surface pressure (P) and the surface pressure of the albumin
FIGURE 4 The relative adsorption (RA) is the difference between the
sample surface pressure (P) and the surface pressure of the albumin-only
isotherm (PAlb, red curve in Fig. 3 b), divided by the difference between the
surface pressure for the saturated isotherm (.1% PEG in Fig. 3 b) andPAlb,
RA ¼ ðPPAlbÞ=ðPsaturated PAlbÞjA0 . All surface pressures were evalu-
ated by averaging over the same trough area denoted by the shaded area in
Fig. 3 b. The solid line is a good ﬁt to the data showing the exponential
dependence of RA on the polymer concentration as predicted by Eqs. 1–3,
consistent with the depletion attraction lowering the energy barrier to surfac-
tant adsorption.
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only isotherm (PAlb, red curve in Fig. 3 b), divided by the
difference between the surface pressure for the saturated
isotherm (.1% PEG in Fig. 3 b) and PAlb, RA ¼ ðP
PAlbÞ=ðPsaturated PAlbÞjA0 . All surface pressures were
evaluated by averaging over the same trough area (Ao),
denoted by the shaded area in Fig. 3 b. This region showed
the maximum variation in adsorption. From Eqs. 1 and 2, the
relative adsorption with albumin and PEG in the subphase
compared to a clean interface should be an exponential





¼ lnðRAÞ ¼ a1bfp ¼ a1b9CPEG;
(3)
in which b, b9, and a are constants for a given Survanta and
albumin concentration. While there is some scatter in the
data, the exponential dependence of the surfactant adsorp-
tion on the PEG concentration is clear from the best-ﬁt line.
This shows that the depletion attraction lowers the steric and
electrostatic energy barrier to adsorption. The relative ad-
sorption increases by approximately a factor of 50 as the
PEG concentration is increased from 0 to 0.8 wt %. Higher
concentrations of PEG lead to minimal increases in adsorp-
tion, as the adsorption has been restored to the rate for a clean
interface, which is likely diffusion-limited.
DISCUSSION
Inhibition of surfactant adsorption by surface-active con-
taminants (here serum proteins) are consistent with the phys-
iological processes that accompany ARDS development and
severity:
1. Surface-active proteins and lysolipids resulting from the
combination of inﬂammation and increased alveolar epi-
thelial permeability adsorb to the alveolar interface.
2. The protein layer creates an electrostatic and steric energy
barrier that exponentially decreases surfactant adsorption.
3. Less surfactant adsorption means that low surface
tensions cannot be reached during normal breathing.
4. Hydrophilic, nonadsorbing polymers can provide sufﬁ-
cient depletion attraction to overcome the energy barrier
and reestablish normal surfactant adsorption.
The attractive depletion forces generated by the hydro-
philic polymers balance the repulsive forces generated by
steric and electrostatic interactions between the serum pro-
teins and the anionic surfactant aggregates to restore diffu-
sion-limited adsorption.
These results also suggest a role in the promotion of
surfactant adsorption for the hyaluronan (HA) normally
present in the alveolus. HA is a natural polysaccharide that is
secreted by alveolar epithelial cells into the alveolar sub-
phase ﬂuid at concentrations of ;4000 mg/l (49); HA, like
PEG, provides an attractive depletion attraction that can
promote surfactant adsorption. The magnitude and range of
the depletion attraction increases with molecular weight (26);
however, there is likely both an optimal polymer concentra-
tion and molecular weight to enhance adsorption, as the
diffusivity strongly decreases (Deff in Eq. 1) with increasing
polymer concentration and molecular weight. The HA in the
lung epithelial ﬂuid is ;220 kDa, which is dramatically less
than that of the lung interstitium at ;3000 kDa (49). This
suggests that the optimal molecular weight to promote sur-
factant adsorption may be different than that required to oc-
cupy the interstitial space between cells. During lung injury
and disease, HA can be broken down by enzymatic action to
produce smaller molecular weight fragments that may be
inﬂammatory (49), but may also not provide sufﬁcient de-
pletion attraction to insure reliable surfactant adsorption,
especially in the presence of serum proteins. Our results show
that it is possible that the increased serum and inﬂammatory
protein concentration and the modiﬁed hyaluronan molec-
ular weight and concentration act in an unfortunate concert to
reduce the rate of surfactant adsorption.
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